Bumrungrad International Hospital (BH) Stock Price, Fundamentals & Analysis

What BH does

Bumrungrad International Hospital (BH) owns and operates hospitals and healthcare centres in Thailand and internationally. It offers services across many specialties, from allergy and cardiology to orthopaedics, oncology, fertility, and travel medicine, and runs clinics focused on areas such as breastfeeding, COVID-19 recovery, IVF, and vaccines. The company is listed on the Stock Exchange of Thailand and is part of the SET50 index, which tracks the exchange's largest stocks.

Key numbers explained

• The current price is 197.5 THB, up 0.77% today, with a 52-week range of 136 – 214 THB.
• The trailing P/E ratio of 22.5 shows how much investors pay per baht of recent earnings; the forward P/E ratio of 20.2 uses expected future earnings.
• The dividend yield is 4.05%, meaning the annual dividend represents about 4% of the current price, with 57% of trailing earnings paid out.
• The ex-dividend date is 28 Aug 2026; the beta of 0.18 suggests the stock has historically moved much less than the broader market.
• Revenue, trailing 12 months, is 25.66 mld. THB, growing 2.9% year over year, with a profit margin of 29.6% and operating margin of 36.7%.
• The return on equity is 27%, and the debt-to-equity ratio of 0.4 indicates relatively low leverage compared with equity.

What to watch

Investors typically monitor BH alongside peers such as Hangzhou Tigermed Consulting (300347), Sino Biopharm (1177), and JD Health (6618), as well as healthcare names like Haleon (HLN) and Ansell (ANN). For a hospital operator, common factors include international patient volumes, currency movements, regulatory changes in Thailand, and competition from peers such as Bangkok Dusit Medical Service (BDMS). The next earnings report is scheduled for 12 Nov 2026.